144 related articles for article (PubMed ID: 31024941)
1.
Setthawongsin C; Tangkawattana S; Rungsipipat A; Techangamsuwan S
Front Vet Sci; 2019; 6():104. PubMed ID: 31024941
[No Abstract] [Full Text] [Related]
2. Effect of recombinant feline interferon-omega alone and in combination with chemotherapeutic agents on putative tumour-initiating cells and daughter cells derived from canine and feline mammary tumours.
Penzo C; Ross M; Muirhead R; Else R; Argyle DJ
Vet Comp Oncol; 2009 Dec; 7(4):222-9. PubMed ID: 19891692
[TBL] [Abstract][Full Text] [Related]
3. Conventional-Vincristine Sulfate vs. Modified Protocol of Vincristine Sulfate and L-Asparaginase in Canine Transmissible Venereal Tumor.
Setthawongsin C; Teewasutrakul P; Tangkawattana S; Techangamsuwan S; Rungsipipat A
Front Vet Sci; 2019; 6():300. PubMed ID: 31620453
[No Abstract] [Full Text] [Related]
4. Adjuvant immunotherapy of feline fibrosarcoma with recombinant feline interferon-omega.
Hampel V; Schwarz B; Kempf C; Köstlin R; Schillinger U; Küchenhoff H; Fenske N; Brill T; Hirschberger J
J Vet Intern Med; 2007; 21(6):1340-6. PubMed ID: 18196745
[TBL] [Abstract][Full Text] [Related]
5. Feline immunodeficiency virus lacks sensitivity to the antiviral activity of feline IFN-gamma.
Tanabe T; Yamamoto JK
J Interferon Cytokine Res; 2001 Dec; 21(12):1039-46. PubMed ID: 11798461
[TBL] [Abstract][Full Text] [Related]
6. Antiproliferation and colony-forming inhibition activities of recombinant feline interferon (rFeIFN) on various cells in vitro.
Priosoeryanto BP; Tateyama S; Yamaguchi R; Uchida K
Can J Vet Res; 1995 Jan; 59(1):67-9. PubMed ID: 7704845
[TBL] [Abstract][Full Text] [Related]
7. Activity of feline interferon-omega after ocular or oral administration in cats as indicated by Mx protein expression in conjunctival and white blood cells.
Bracklein T; Theise S; Metzler A; Spiess BM; Richter M
Am J Vet Res; 2006 Jun; 67(6):1025-32. PubMed ID: 16740097
[TBL] [Abstract][Full Text] [Related]
8. Effect of tumor infiltrating lymphocytes on the expression of MHC molecules in canine transmissible venereal tumor cells.
Hsiao YW; Liao KW; Hung SW; Chu RM
Vet Immunol Immunopathol; 2002 Aug; 87(1-2):19-27. PubMed ID: 12052339
[TBL] [Abstract][Full Text] [Related]
9. Oral and subcutaneous therapy of canine atopic dermatitis with recombinant feline interferon omega.
Litzlbauer P; Weber K; Mueller RS
Cytokine; 2014 Mar; 66(1):54-9. PubMed ID: 24548425
[TBL] [Abstract][Full Text] [Related]
10. The biological effects of five feline IFN-alpha subtypes.
Baldwin SL; Powell TD; Sellins KS; Radecki SV; Cohen JJ; Milhausen MJ
Vet Immunol Immunopathol; 2004 Jun; 99(3-4):153-67. PubMed ID: 15135982
[TBL] [Abstract][Full Text] [Related]
11. Autologous canine immunotherapy: short-time generated dendritic cells loaded with canine transmissible venereal tumor-whole lysate.
Franco-Molina MA; Ramos-Zayas Y; Coronado-Cerda EE; Mendoza-Gamboa E; Zapata-Benavides P; Santana-Krymskaya SE; Tamez-Guerra R; Rodríguez-Padilla C
Immunopharmacol Immunotoxicol; 2018 Oct; 40(5):437-443. PubMed ID: 30507311
[TBL] [Abstract][Full Text] [Related]
12. Effects of human recombinant alpha-2b interferon and feline recombinant omega interferon on in vitro replication of feline herpesvirus-1.
Siebeck N; Hurley DJ; Garcia M; Greene CE; Köstlin RG; Moore PA; Dietrich UM
Am J Vet Res; 2006 Aug; 67(8):1406-11. PubMed ID: 16881854
[TBL] [Abstract][Full Text] [Related]
13. The role of the multi-drug resistance 1, p53, b cell lymphoma 2, and bcl 2-associated X genes in the biologic behavior and chemotherapeutic resistance of canine transmissible venereal tumors.
Alzate JM; Montoya-Florez LM; Pérez JE; Rocha NS; Pedraza-Ordonez FJ
Vet Clin Pathol; 2019 Dec; 48(4):730-739. PubMed ID: 31777108
[TBL] [Abstract][Full Text] [Related]
14. Limited efficacy of topical recombinant feline interferon-omega for treatment of cats with acute upper respiratory viral disease.
Ballin AC; Schulz B; Helps C; Sauter-Louis C; Mueller RS; Hartmann K
Vet J; 2014 Dec; 202(3):466-70. PubMed ID: 25457261
[TBL] [Abstract][Full Text] [Related]
15. Clinical effects of the recombinant feline interferon-omega on experimental parvovirus infection in beagle dogs.
Ishiwata K; Minagawa T; Kajimoto T
J Vet Med Sci; 1998 Aug; 60(8):911-7. PubMed ID: 9764403
[TBL] [Abstract][Full Text] [Related]
16. Receptors for recombinant feline interferon-omega in hemocytes of the Japanese pearl oyster Pinctada fucata martensii.
Miyazaki T; Taniguchi T; Hirayama J; Nozawa N
Dis Aquat Organ; 2002 Aug; 51(2):135-8. PubMed ID: 12363085
[TBL] [Abstract][Full Text] [Related]
17. Clinical trial results on the use of a recombinant feline interferon-omega to protect Japanese pearl oysters Pinctada fucata martensii from akoya-virus infection.
Miyazaki T; Nozawa N; Kobayashi T
Dis Aquat Organ; 2000 Oct; 43(1):15-26. PubMed ID: 11129377
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the efficacy of the subcutaneous low recombinant feline interferon-omega administration protocol for feline chronic gingivitis-stomatitis in feline calicivirus-positive cats.
Matsumoto H; Teshima T; Iizuka Y; Sakusabe A; Takahashi D; Amimoto A; Koyama H
Res Vet Sci; 2018 Dec; 121():53-58. PubMed ID: 30359811
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of recombinant feline interferon on the replication of feline enteropathogenic viruses in vitro.
Mochizuki M; Nakatani H; Yoshida M
Vet Microbiol; 1994 Mar; 39(1-2):145-52. PubMed ID: 7515537
[TBL] [Abstract][Full Text] [Related]
20. In vitro growth inhibition activities of recombinant feline interferon on all lines derived from canine tumours.
Tateyama S; Priosoeryanto BP; Yamaguchi R; Uchida K; Ogiwara K; Suchiya AT
Res Vet Sci; 1995 Nov; 59(3):275-7. PubMed ID: 8588106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
